IVA: 2026 MASH Phase 3 Readout Will Underpin Bullish Repricing Outlook

Analysts have trimmed their fair value estimate for Inventiva slightly from about €10.00 to about €9.97, pointing to updated assumptions around profit margins and a higher future P/E that balance recent caution from one research house with a more bullish initiation from another.

Analyst Commentary

Bullish Takeaways

Bullish analysts see the slightly higher assumed future P/E as support for the idea that investors may be willing to pay up for the stock if execution on the current pipeline stays on track.
They view the fresh initiation as a sign that the story is reaching a wider research audience, which can help trading liquidity and the visibility of the investment case.
Supportive commentary around the long term opportunity suggests some analysts are comfortable with a fair value near €10.00, even after the small trim. This indicates they still see room for upside if milestones are met.
Bullish analysts tend to frame the updated model assumptions as fine tuning rather than a reset. This can be reassuring for investors focused on long term growth potential.

Bearish Takeaways

Bearish analysts are emphasizing more conservative profit margin assumptions, which can weigh on earnings power and justify only a marginal change in fair value rather than a higher target.
The recent cut to a price target in US$ terms signals that some are less confident about near term execution risks, even if the long term thesis is intact.
More cautious views highlight that the higher future P/E assumption also embeds higher execution risk, since any setback could have an outsized effect on valuation.
The balance between a target reduction and a bullish initiation leaves a mixed signal for investors, as not all analysts agree on how quickly the company can translate its plans into sustainable earnings.

What's in the News

Inventiva appointed Axel-Sven Malkomes as Chief Financial Officer, bringing over 30 years of experience across investment banking, corporate leadership, and private equity in life sciences and healthcare. Long serving finance leaders Jean Volatier and Nathalie Harroy move into roles where they continue to support the company's development (Key Developments).
Jean Volatier transitions to EVP Finance & Corporate Social Responsibility to support key priorities, and Nathalie Harroy remains with the company, which keeps significant institutional knowledge within Inventiva's finance function (Key Developments).
In its 20-F filed on April 8, 2026 for the year ended December 31, 2025, Inventiva received an unqualified opinion from auditor KPMG LLP with an expressed doubt about the company's ability to continue as a going concern (Key Developments).

Valuation Changes

Fair Value was trimmed slightly from about €10.00 to about €9.97, reflecting updated assumptions across the model.
The Discount Rate was adjusted marginally from about 6.93% to about 6.90%, a small change in the assumed risk profile used in the valuation.
Revenue Growth was kept effectively unchanged at around 193.97%, signaling no shift in the top line growth assumption used here.
The Net Profit Margin was reduced significantly from about 39.59% to about 6.59%, which meaningfully lowers the earnings power built into the model.
The Future P/E was raised to a very large multiple, moving from about 45.7x to more than 270x, which builds in a higher valuation sensitivity to execution on the plan.

6 views

Key Takeaways

Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency.
Key partnerships in Asia and financial strength ensure market penetration and support sustained investment, boosting future earnings potential.
Heavy reliance on lanifibranor and halting other projects may hinder innovation and diversification, posing risks to revenue and future earnings.

Catalysts

About Inventiva

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.What are the underlying business or industry changes driving this perspective?

The ongoing Phase III clinical trial for lanifibranor in MASH is anticipated to complete patient recruitment in the first half of 2025, with top-line results expected in the second half of 2026. This positions lanifibranor potentially as the second oral drug approved for MASH in the United States, which could significantly increase revenue.
Inventiva has strategically prioritized resources towards lanifibranor’s development, including regulatory preparation and commercialization efforts, while cutting preclinical activities unrelated to lanifibranor and reducing workforce by approximately 50%. This focus could lead to improved net margins by optimizing operational efficiency.
Partnerships in key Asian markets with licenses in Japan, South Korea, and China are expected to position lanifibranor as a leading treatment for MASH in these regions. Collaborations with partners like Hepalys and CTTQ could increase earnings from milestone payments and future market penetration.
Strong financial backing from dilutive and nondilutive financing operations, including a structured deal worth up to €348 million, ensures a cash runway sufficient to reach September 2026 with the second tranche. This financial strength can support sustained investment in commercialization, potentially boosting future earnings.
With no other oral liver-targeted drug candidates in Phase III for MASH, Inventiva’s unique position in a growing market with a high prevalence of conditions like type 2 diabetes enhances the drug’s potential impact on net revenue growth, given the unmet medical needs in this segment.

Inventiva Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Inventiva's revenue will grow by 194.0% annually over the next 3 years.
Analysts are not forecasting that Inventiva will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Inventiva's profit margin will increase from -5238.0% to the average GB Biotechs industry of 6.6% in 3 years.
If Inventiva's profit margin were to converge on the industry average, you could expect earnings to reach €11.3 million (and earnings per share of €0.04) by about May 2029, up from -€354.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €232.7 million in earnings, and the most bearish expecting €-336.1 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 273.7x on those 2029 earnings, up from -2.5x today. This future PE is greater than the current PE for the GB Biotechs industry at 16.2x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.9%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The decision to stop all preclinical activities not related to lanifibranor and reduce the workforce by approximately 50% could impact the company's ability to innovate and diversify, potentially affecting future revenues and margins.
The net loss for the full year 2024 was €184.2 million, significantly up from €110.4 million in 2023, indicating higher operating costs or expenses, which could affect the company's profitability and net margins.
Revenues decreased from €17.5 million in 2023 to €9.2 million in 2024, highlighting potential challenges in achieving consistent income streams, which could impact future earnings.
Heavy reliance on the success of lanifibranor, especially as other projects are halted, poses a risk to revenue if the drug fails to perform as expected in clinical trials or the market.
The need for additional financing beyond current measures suggests potential cash flow issues, which might lead to further dilution or debt, impacting net margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €9.97 for Inventiva based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €15.37, and the most bearish reporting a price target of just €7.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €171.8 million, earnings will come to €11.3 million, and it would be trading on a PE ratio of 273.7x, assuming you use a discount rate of 6.9%.
Given the current share price of €4.25, the analyst price target of €9.97 is 57.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Inventiva?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress